research
sought
therapeut
applic
monoclon
antibodi
sinc
develop
howev
murinederiv
monoclon
antibodi
may
caus
immunogen
respons
human
patient
reduc
therapeut
efficaci
chimer
human
antibodi
develop
less
like
provok
immun
reaction
human
patient
murinederiv
antibodi
antibodi
fragment
bispecif
antibodi
antibodi
produc
use
phage
display
system
genet
modifi
plant
anim
may
aid
research
develop
new
use
monoclon
antibodi
treatment
diseas
monoclon
antibodi
may
number
promis
potenti
therapeut
applic
treatment
asthma
autoimmun
diseas
cancer
poison
septicemia
substanc
abus
viral
infect
diseas
n
kohler
milstein
revolution
field
immunolog
develop
monoclon
antibodi
mab
sinc
time
mani
mab
develop
use
diagnost
procedur
immunotherapi
ever
sinc
observ
therapeut
use
heterolog
mab
elicit
immunogen
respons
human
signific
research
effort
devot
toward
creat
chimer
human
antibodi
use
human
patient
major
achiev
product
mab
transgen
plant
anim
use
phage
display
librari
creat
custom
antibodi
defin
affin
specif
review
describ
rodent
chimer
human
antibodi
use
vari
degre
success
treat
cancer
septicemia
autoimmun
disord
infecti
diseas
also
describ
recent
applic
antibodi
engin
use
bispecif
antibodi
antibodi
fragment
immunotherapi
von
behr
kitasato
discov
serum
vaccin
person
contain
certain
substanc
term
antibodi
treat
diphtheria
antiserum
rais
toxin
basi
research
tetanu
toxin
trypanosom
parasit
ehrlich
propos
sidechain
theori
antibodi
format
hypothes
physiolog
activ
substanc
includ
toxin
attach
cell
surfac
receptor
produc
respons
toxincel
interact
eject
cell
bloodstream
lead
circul
antibodi
howev
scientist
understand
antibodi
becom
suffici
lay
foundat
develop
mab
jern
postul
theori
natur
select
antibodi
format
anim
vaccin
antigen
expect
produc
sever
distinct
antibodi
sever
epitop
antigen
frank
macfarlan
burnet
subsequ
refin
expand
jern
theori
burnet
clonal
select
theori
gener
known
postul
cell
specif
synthes
type
antibodi
spontan
gener
due
random
somat
mutat
matur
immun
system
cell
prolifer
expos
antigen
time
porter
isol
fragment
antigen
bind
fab
fragment
crystallin
fc
proteolyt
cleav
rabbit
antibodyproduc
cell
difficult
maintain
cultur
die
day
addit
polyclon
antibodi
could
obtain
littlefield
develop
way
isol
hybrid
cell
parent
cell
line
use
hypoxanthineaminopterinthymidin
hat
select
media
khler
milstein
provid
outstand
proof
clonal
select
theori
result
heterokaryonscel
hybrid
form
fusion
normal
malign
cell
twentyf
year
kohler
milstein
produc
first
monoclon
antibodi
dramat
progress
made
use
antibodi
diagnost
purpos
use
mab
treat
diseas
haveuntil
recentlyremain
somewhat
limit
howev
review
indic
potenti
mab
aid
treatment
wide
rang
diseas
begin
realiz
antibodi
yshape
protein
compos
peptid
call
heavi
light
chain
end
vari
antibodi
antibodi
combin
heavi
light
chain
bind
particular
antigen
site
glycoprotein
chain
fold
domain
amino
acid
becom
twist
immunoglobulin
ig
fold
stabil
disulfid
bond
structur
ig
molecul
consist
heavi
chain
light
chain
link
disulfid
bond
human
immunoglobulin
divid
class
isotyp
base
amino
acid
composit
heavi
chain
denot
iga
igd
ige
igg
igm
respect
kind
light
chain
k
l
common
class
four
subclass
igg
subclass
iga
exist
distinct
function
secretori
iga
exist
dimer
form
held
togeth
j
chain
associ
secretori
compon
help
pass
cell
membran
chain
constant
domain
bind
host
effector
molecul
variabl
domain
bind
target
antigen
light
chain
variabl
v
l
constant
domain
c
l
wherea
heavi
chain
variabl
v
h
either
chain
constant
domain
heavi
chain
depend
upon
isotyp
class
variabl
domain
contain
region
known
hypervari
loop
also
known
complementaritydetermin
region
cdr
identifi
antigen
amino
acid
variabl
fv
domain
known
framework
residu
act
scaffold
support
loop
v
l
v
h
c
h
c
l
c
h
domain
pair
c
h
domain
carbohydr
side
chain
attach
pair
fold
constant
domain
may
homolog
among
differ
speci
allow
hybrid
domain
eg
mousehuman
produc
variabl
domain
confer
specif
affin
cdr
amino
acid
sequenc
extrem
variabl
play
larg
role
interact
target
antigen
chain
type
region
distanc
amino
terminu
character
domain
thu
c
h
domain
refer
second
constant
domain
heavi
chain
upon
digest
papain
antibodi
molecul
cleav
aminotermin
side
disulfid
bridg
ident
fab
fc
fragment
wherea
pepsin
cleav
antibodi
carboxytermin
side
disulfid
bridg
f
ab
fragment
contain
arm
antibodi
mani
small
piec
fc
fragment
current
follow
avail
whole
antibodi
enzymat
produc
fab
fragment
engin
singlechain
fv
scfv
antibodi
consist
v
h
v
l
connect
flexibl
peptid
linker
diabodi
noncoval
dimer
scfv
minibodi
scfvc
h
dimer
heavi
chain
igg
found
speci
camelida
famili
devoid
light
chain
refer
v
hh
first
mab
describ
kohler
milstein
creat
fusion
murin
myeloma
cell
murineantibodysecret
lymphocyt
myeloma
cell
immort
b
lymphocyt
capabl
secret
homogen
antibodi
immort
myeloma
cell
lack
enzym
hypoxanthin
guanosin
phosphoribosyl
transferas
hgprt
sensit
hat
media
howev
hybrid
cell
known
hybridoma
gener
fusion
myeloma
cell
antibodyproduc
b
cell
surviv
hat
media
spleen
b
lymphocyt
contribut
hgprt
gene
hybrid
cell
henc
unfus
myeloma
cell
spleen
cell
die
hat
media
convent
method
gener
mab
hybridoma
technolog
spleen
cell
immun
mice
fuse
murin
myeloma
cell
wherea
myeloma
cell
impart
immort
hybridoma
allow
cell
cultiv
indefinit
immun
spleen
bcell
confer
antigen
specif
hybridoma
deriv
singl
cell
cell
within
hybridoma
cell
line
ident
make
antibodi
molecul
antigenbind
site
isotyp
henc
call
mab
among
sever
excel
review
detail
mab
product
hybridoma
recent
review
dean
shepherd
initi
attempt
bypass
mous
make
human
mab
involv
fusion
human
immun
spleen
lymphocyt
nonsecret
human
myeloma
partner
obtain
hybrid
cell
continu
secret
specif
antibodi
howev
poor
fusion
human
myeloma
unsatisfactori
perform
hybrid
cell
difficulti
access
immun
lymphocyt
prevent
success
although
heteromyelomaswhich
fusion
human
mous
myelomaswork
better
hybrid
usual
unstabl
attempt
use
mous
myeloma
cell
creat
hybrid
deriv
human
mab
led
loss
human
chromosom
inabl
make
human
ig
unfortun
vitro
immun
limit
inabl
produc
secondari
respons
absenc
affin
matur
process
occur
vivo
affin
matur
process
complex
phenomenon
consequ
intens
bcell
prolifer
somat
hypermut
ig
variabl
domain
gene
select
b
cell
highaffin
antigen
bind
occur
special
microenviron
germin
center
within
lymphoid
tissu
thu
search
ideal
fusion
partner
gener
human
mab
difficult
epsteinbarr
viru
ebv
techniqu
immort
b
lymphocyt
prefer
immort
b
cell
alway
replic
exactli
vivo
antibodi
respons
tissu
cell
select
manipul
subject
laboratori
may
alter
antibodi
specif
protocol
prepar
ebv
viru
b
cell
cell
fusion
describ
elsewher
method
use
largescal
product
mab
may
includ
gener
ascit
tumor
mice
vitro
mammalian
cell
cultur
ferment
use
bioreactor
continu
perfus
cultur
system
key
issu
scaleup
product
growth
media
ferment
size
ferment
time
purif
procedur
purif
downstream
process
accomplish
chromatographi
fragment
conjug
chelat
agent
ultrafiltr
control
precipit
recent
techniqu
produc
antibodylik
molecul
use
known
phage
display
librari
involv
construct
v
h
v
l
gene
librari
express
surfac
filament
bacteriophag
develop
phage
display
method
requir
repeat
pan
screen
differ
antibodi
base
affin
specif
antigen
antibodi
gene
link
bacteriophag
coat
protein
gene
bacteriophag
fusion
gene
use
infect
bacteria
creat
phage
display
librari
result
bacteriophag
express
fusion
protein
display
surfac
phage
display
librari
compris
recombin
phage
display
differ
antigenbind
site
surfac
phage
express
antigenbind
domain
specif
particular
antigen
detect
isol
bind
surfac
coat
antigen
librari
v
h
v
l
gene
may
gener
nonimmun
donor
immun
donor
immun
respons
particular
antigen
synthet
librari
consist
antibodi
fragment
one
promis
way
increas
antibodi
yield
develop
new
antibodi
may
use
genet
alter
anim
plant
abgenix
compani
fremont
ca
develop
transgen
xenomous
mous
antibodyproduc
gene
inactiv
function
replac
approxim
human
ig
gene
loci
germlin
configur
code
heavi
light
chain
upon
immun
specif
human
nonhuman
antigen
xenomous
gener
mab
fulli
human
ig
high
affin
antigenbind
specif
xenomous
strain
produc
specif
isotyp
also
creat
gener
panel
divers
highli
specif
mab
kirin
breweri
compani
japan
develop
anoth
transgen
mous
known
transchromo
mous
endogen
igh
igg
loci
transchromo
mous
inactiv
harbor
individu
human
chromosom
fragment
deriv
human
chromosom
contain
whole
human
ig
lightand
heavychain
loci
respect
mice
capabl
produc
everi
subtyp
fulli
human
ig
includ
iga
igm
transgen
mous
model
human
antibodi
high
affin
immun
antigen
natur
select
murin
immun
system
via
affin
matur
process
therebi
show
increas
divers
mab
transgen
mice
may
suitabl
altern
chimer
human
antibodi
product
use
phage
display
system
creat
less
immunogen
novel
antibodi
instanc
transgen
mice
express
mab
coronaviru
milk
develop
rumin
anim
cow
goat
sheep
produc
rel
larg
amount
milk
geneticallymodifi
member
speci
could
also
use
produc
larg
quantiti
therapeut
protein
includ
mab
plant
may
potenti
sourc
recombin
protein
includ
mab
plant
viru
vector
tobacco
mosaic
viru
may
use
make
mab
transgen
tobacco
plant
may
also
use
largescal
product
recombin
iga
use
passiv
mucos
immunotherapi
mab
could
ad
toothpast
effect
protect
bacteria
caus
tooth
decay
recombin
antigen
obtain
plant
may
also
therapeut
applic
instanc
attempt
immun
mice
escherichia
coli
heat
labil
enterotoxin
b
produc
transgen
tobacco
potato
plant
prove
promis
hepat
b
viral
surfac
protein
produc
transgen
tobacco
plant
shown
immunogen
mice
gene
code
murin
malign
bcell
specif
marker
insert
tobacco
mosaic
viru
cultiv
immunogen
protein
tobacco
plant
may
eventu
use
develop
vaccin
nonhodgkin
lymphoma
immunotherapeut
protein
develop
includ
norwalk
viru
capsid
protein
produc
tobacco
potato
cholera
toxin
ctb
produc
potato
hepat
b
antigen
produc
tobacco
antihuman
igg
use
detect
nonagglutin
antibodi
produc
alfalfa
human
antiherp
simplex
viru
hsv
grown
soybean
food
drug
administr
fda
consid
antibodi
biopharmaceut
mab
applic
regul
agenc
center
biolog
evalu
research
cber
center
drug
evalu
research
fda
creat
point
consid
document
advis
manufactur
factor
consid
product
test
mab
intend
human
use
identifi
inform
appear
investig
new
drug
biolog
licens
applic
point
consid
document
serv
indic
agenc
current
think
mab
product
human
use
agenc
recommend
aim
protect
human
health
virus
cellular
dna
antibodyproduc
cell
malign
phenotyp
may
integr
host
cell
transform
accordingli
among
point
consid
sever
stepssuch
take
care
ensur
puriti
immunoconjug
demonstr
abil
purif
scheme
remov
adventiti
agentsdesign
prevent
contamin
final
product
human
pathogen
manufactur
must
also
adher
anim
care
standard
detail
step
prevent
contamin
cell
cultur
point
consid
document
includ
list
normal
human
tissu
use
crossreact
test
test
murin
virus
organ
consid
dosimetri
estim
fda
recogn
speci
differ
anim
model
express
antigen
interest
crossreact
epitop
alway
avail
agenc
also
publish
guidanc
entitl
preclin
safeti
evalu
biotechnolog
deriv
pharmaceut
base
intern
confer
harmon
technic
requir
begin
phase
clinic
studiesconduct
assess
safeti
drug
mechan
actionth
fda
recommend
research
conduct
vivo
vitro
test
mab
assess
crossreact
human
tissu
nontargettissu
bind
preclin
safeti
test
aim
evalu
immunogen
crossreact
stabil
effector
function
mab
metabol
carcinogen
genotox
product
also
evalu
guidanc
also
publish
mab
use
reagent
drug
manufactur
guidanc
emphas
biolog
safeti
perform
characterist
reagent
potenti
presenc
residu
amount
reagent
final
product
fda
gener
principl
test
manufactur
broadli
applic
mani
class
antibodi
includ
produc
phage
display
system
transgen
plant
anim
depend
express
system
use
fda
guidanc
document
cber
point
produc
biolog
also
referenc
human
monoclon
antibodi
rodent
mab
excel
affin
specif
gener
use
convent
hybridoma
technolog
use
clinic
medicin
limit
due
immun
respons
elicit
human
instanc
human
antimous
antibodi
hama
respons
compromis
clinic
effect
murin
mab
although
hama
respons
direct
murin
constant
region
repres
major
antigen
featur
mous
ig
signific
respons
also
direct
toward
murin
variabl
region
result
patient
may
mount
immun
respons
inject
murin
antibodi
lead
allerg
immun
complex
hypersensit
rapid
clearanc
antibodi
reduc
clinic
efficaci
initi
morrison
colleagu
introduc
chimer
mab
show
sever
advantag
unmodifi
rodent
antibodi
gener
chimera
combin
human
constant
region
intact
rodent
variabl
region
replic
rodent
antibodi
variabl
region
pcr
clone
eukaryot
express
vector
contain
human
constant
region
ideal
allow
better
interact
human
effector
cell
complement
system
fc
region
littl
influenc
structur
fv
region
chimer
construct
affin
specif
virtual
unchang
rodent
chimer
antibodi
caus
apoptosi
similar
rate
intens
target
cell
vitro
although
chimer
antibodi
help
solv
problem
associ
use
rodent
mab
still
show
signific
immunogen
human
approxim
mous
sequenc
caus
humanantichimer
antibodi
respons
human
antibodi
contain
cdr
rodent
variabl
region
graft
onto
human
variabl
region
framework
introduc
overcom
defici
earli
work
recombin
chimer
rodenthuman
antibodi
happen
mid
late
greg
winter
colleagu
demonstr
function
humanlik
antibodi
could
creat
graft
antigenbind
cdr
variabl
domain
rodent
antibodi
onto
human
variabl
domain
numer
human
antibodi
design
construct
mani
current
evalu
clinic
trial
effici
procedur
construct
human
antibodi
develop
first
step
clone
sequenc
complementari
dna
cdna
code
variabl
domain
mous
antibodi
human
mous
hybridoma
cell
line
grown
appropri
cultur
medium
cell
harvest
rna
isol
polymeras
chain
reaction
pcr
primer
hybrid
end
mous
leader
sequenc
end
mous
constant
region
design
clone
light
chain
variabl
region
heavi
chain
variabl
region
cdna
synthes
total
rna
follow
pcr
amplif
light
heavi
chain
specif
primer
posit
bacteri
coloni
contain
mous
variabl
region
screen
construct
chimer
antibodi
involv
modifi
clone
mous
leadervari
region
use
pcr
primer
creat
restrict
enzym
site
conveni
insert
express
vector
incorpor
sequenc
effici
eukaryot
translat
incorpor
splicedonor
site
rna
splice
variabl
constant
region
adapt
mous
light
heavi
chain
leadervari
region
insert
vector
contain
exampl
human
cytomegaloviru
enhanc
promot
transcript
human
light
heavi
chain
constant
region
neomycin
gene
select
transform
cell
simian
viru
origin
replic
co
cell
vector
design
express
chimer
reshap
human
light
heavi
chain
mammalian
cell
design
construct
engin
human
antibodi
requir
analysi
primari
amino
acid
sequenc
mous
variabl
region
identifi
residu
critic
form
antigenbind
site
structur
model
mous
variabl
region
built
basi
homolog
known
antibodi
variabl
region
framework
region
fr
new
variabl
region
model
fr
structur
similar
immunoglobulin
variabl
region
design
process
involv
select
human
light
heavi
chain
variabl
region
serv
templat
construct
reshap
human
antibodi
mous
cdr
join
fr
select
human
variabl
region
primari
amino
acid
sequenc
care
analyz
ascertain
whether
would
recreat
antigenbind
site
mimic
origin
mous
antibodi
within
fr
amino
acid
differ
mous
human
sequenc
examin
rel
import
amino
acid
format
antigenbind
site
evalu
minimum
chang
fr
desir
close
match
sequenc
natur
human
antibodi
potenti
glycosyl
site
fr
either
mous
human
sequenc
need
identifi
influenc
antigen
bind
consid
dna
sequenc
code
reshap
human
variabl
region
either
made
synthet
base
exist
sequenc
similar
newli
design
reshap
human
variabl
region
modifi
pcr
special
design
oligonucleotid
primer
human
variabl
region
togeth
leader
sequenc
clone
mammalian
express
vector
alreadi
contain
human
constant
region
human
variabl
region
link
desir
constant
region
via
intron
preliminari
express
analysi
reshap
human
antibodi
done
cotransfect
mammalian
cellexpress
vector
code
human
light
chain
code
human
heavi
chain
vector
replic
co
cell
transient
express
secret
reshap
human
antibodi
concentr
antibodi
produc
analyz
use
enzymelink
immunosorb
assay
specif
chang
amino
acid
framework
region
may
also
requir
preserv
orient
structur
rodent
cdr
requir
bind
comput
model
use
databas
contain
human
variabl
gene
identifi
sequenc
homolog
rodent
v
region
comput
model
rodent
fv
identifi
noncdr
residu
interact
cdr
sequenc
choic
made
regard
residu
need
includ
variabl
region
antibodi
human
way
may
bind
affin
onethird
greater
correspond
murin
antibodi
allergen
also
significantli
reduc
patient
exhibit
hama
reaction
murin
antibodi
wherea
similar
reaction
human
antibodi
human
mab
still
sever
practic
difficulti
first
detail
knowledg
antibodi
structur
function
requir
second
method
effici
construct
human
mab
limit
third
unpredict
immunogen
may
result
new
amino
acid
sequenc
introduc
balanc
affin
retent
fourth
antibodi
repertoir
limit
anim
progenitor
mab
origin
fifth
rodent
mab
produc
hybridoma
must
isol
thoroughli
character
howev
obstacl
human
gradual
surmount
karpa
et
al
report
creat
hatsensit
ouabainresist
human
myeloma
cell
line
fuse
human
lymphoblast
cell
hatsensit
sublin
myeloma
cell
secret
light
chain
fuse
ebvtransform
white
blood
cell
produc
igg
mab
eventu
clone
isol
polyethylen
glycolresist
would
revert
place
hat
medium
standard
polyethylen
glycol
fusion
protocol
follow
fuse
myeloma
cell
ebvtransform
white
cell
fresh
white
cell
obtain
peripher
blood
adult
tonsil
cell
children
author
report
promis
rate
hybridoma
format
stabl
ig
product
high
yield
secret
antibodi
compar
antibodyproduc
cell
line
mous
myeloma
cell
author
develop
hybridoma
secret
cell
month
human
myeloma
cell
line
may
eventu
prove
use
creat
mab
certain
autoimmun
diseas
cancer
techniqu
may
also
make
easier
research
gener
human
mab
use
therapi
antibodi
may
act
directli
bind
target
molecul
induc
apoptosi
inhibit
cell
growth
mimick
block
ligand
interf
key
function
addit
antibodi
may
modul
potenti
drug
therapi
antibodi
may
act
effectora
antibodydepend
cellular
cytotox
adcc
antibodydepend
complementmedi
cascadeor
may
involv
effector
element
cytotoxin
enzym
radioact
isotop
signal
part
immun
system
andor
cytotox
drug
adcc
occur
fc
region
antibodi
recogn
receptor
present
cytotox
cell
natur
killer
cell
macrophag
granulocyt
monocyt
complementmedi
cytotox
ensu
antibodi
bind
prompt
complement
cascad
occur
activ
immunotherapi
accomplish
antigen
provok
longlast
tcell
respons
may
achiev
administ
whole
cancer
cell
extract
use
small
antigen
peptid
isol
tumor
experiment
patient
anim
instanc
mab
mimick
breast
cancerspecif
antigen
elicit
antiidiotyp
antibodi
anoth
way
creat
activ
immun
lead
humor
auto
antibodylik
immun
respons
use
bispecif
molecul
recogn
antigen
target
cell
effector
cell
increas
adcc
effect
mechan
blockad
crucial
ligand
growth
factor
adcc
tumor
cell
kill
fc
receptorbear
cytotox
effector
cell
kill
adcc
proport
amount
antibodi
bound
cell
wherea
blockad
essenti
growth
factor
may
show
effect
receptor
satur
higher
antigen
express
target
cell
increas
antibodi
bind
subsequ
adcc
high
receptor
express
also
make
difficult
prevent
bind
cytokin
ligand
minimum
threshold
bispecif
antibodi
specif
mab
combin
cytotox
immun
effector
cell
instanc
neutral
tumor
bispecif
antibodi
link
tumor
cell
directli
killer
cell
via
cytotox
trigger
molecul
tcell
receptor
fc
receptor
lead
lysi
andor
phagocytosi
effector
cell
although
bispecif
antibodi
enrich
effector
tumor
site
activ
tumor
bound
effector
cell
enabl
crosslink
effector
target
cell
caus
systemwid
immun
activ
tcell
receptor
crosslink
bispecif
antibodi
also
mediat
cellular
cytotox
via
variou
effector
cell
includ
phagocyt
natur
killer
cell
tlymphocyt
anoth
way
use
bind
properti
antibodi
conjug
antibodi
cytotox
drug
radioisotop
toxin
techniqu
conjug
describ
sever
recent
review
articl
mab
conjug
chemotherapeut
drug
doxorubicin
mitomycin
methotrex
chemotherapeut
agent
constitut
cytotox
cytostat
drug
conjug
antibodi
thu
far
howev
drug
shown
poor
specif
target
cell
frequent
lead
toxic
often
antibodi
may
lose
reactiv
upon
conjug
agent
immunotoxin
use
cancer
therapi
conjug
antibodi
combin
plant
ricin
gelonin
saponin
abrin
pokewe
antivir
protein
bacteri
diphtheria
toxin
pseudomona
toxin
toxin
antibodi
specif
toxin
may
inhibit
protein
synthesi
even
picomolar
concentr
natur
toxin
diphtheria
toxin
act
low
concentr
enter
cell
disrupt
key
cellular
process
enzym
may
also
conjug
antibodi
antibodydirect
enzymeprodrug
therapi
enzym
convert
prodrug
activ
form
may
conjug
antibodi
target
desir
locat
use
antibodybind
region
may
effect
local
tumor
chemic
conjug
prodrug
convert
activ
drug
enzym
target
cell
anoth
therapeut
techniqu
reli
use
antibodi
fragment
may
produc
tradit
method
proteolyt
digest
papain
newer
method
may
reduc
damag
bind
site
newer
method
attempt
construct
mimet
combin
multipl
cdr
sever
antibodi
singl
molecul
molecular
weight
substanti
lower
singl
chain
fragment
smaller
size
antibodi
fragment
may
abl
penetr
tissu
tumor
readili
less
immunogen
whole
mab
howev
although
antibodi
fragment
may
better
penetr
whole
antibodi
shorter
halfliv
may
compromis
clinic
use
heteropolymer
antibodi
recent
develop
chemic
link
mous
igg
mab
specif
complement
receptor
site
human
nonhuman
primat
erythrocyt
second
mous
igg
mab
specif
target
antigen
heteropolym
techniqu
base
immun
adher
antibodyantigen
immun
complex
bind
complement
receptor
red
blood
cell
facilit
phagocytosi
complex
introduc
patient
heteropolym
bind
red
blood
cell
target
antigen
antigenantibodi
heteropolym
complex
transport
liver
spleen
complex
destroy
macrophag
wherea
red
blood
cell
return
circul
unharm
wide
varieti
condit
autoimmun
foreign
origin
may
potenti
treat
method
includ
hiv
infect
system
lupu
erythematosu
marburg
viru
infect
myasthenia
gravi
although
mous
antibodi
current
use
techniqu
chimer
mousehuman
antibodi
could
also
construct
may
also
possibl
use
heteropolym
sentinel
inject
antigen
exposur
recent
studi
multipl
infus
heteropolym
provid
nonimmun
monkey
protect
antigen
long
week
milstein
kohler
announc
isol
mab
mani
thought
mab
would
provid
effect
cancer
treatment
howev
earli
clinic
trial
disappoint
produc
mab
tumor
antigen
complex
process
first
protein
peculiar
human
cancer
cell
identifi
mice
inject
human
tumor
cell
antigen
stimul
immun
respons
day
mous
lymphocyt
remov
fuse
myeloma
cell
isol
reproduc
hybrid
cell
specif
predetermin
antigen
rodent
antibodi
alon
use
sever
trial
clinic
effect
often
minim
poor
activ
human
effector
complement
cell
fc
region
murin
antibodi
accompani
hama
respons
substitut
rodent
fc
region
human
fc
fragment
may
help
overcom
effect
discoveri
protooncogen
secondgener
trial
turn
specif
tumor
antigen
could
potenti
target
mab
antibodi
epitheli
cell
surfac
antigen
express
human
colorect
carcinoma
approv
identif
adenocarcinoma
may
reduc
mortal
occurr
rate
colorect
cancer
rituximab
mousehuman
chimer
antibodi
approv
treatment
nonhodgkin
b
cell
lymphoma
rituximab
bind
antigen
b
cell
b
cell
tumor
elicit
natur
immun
respons
kill
malign
cell
recent
anim
trial
shown
potenti
mab
therapi
cancer
increas
epiderm
growth
factor
egf
receptor
express
found
mani
human
cancer
fulli
human
antiegf
receptor
mab
shown
inhibit
human
cancer
growth
vitro
vivo
effort
focus
antibodi
antigen
breast
cancer
patient
cancer
often
mount
immunolog
respons
tumorassoci
antigen
increas
cytotox
lymphocyt
antibodi
sever
tumorreact
antibodi
clone
melanoma
colon
carcinoma
ovarian
breast
lung
tumor
often
antibodi
crossreact
malign
tissu
cell
line
recent
trastuzumab
herceptin
human
mab
bind
directli
protein
approv
fda
treatment
breast
cancer
herceptin
use
treat
metastat
breast
cancer
patient
whose
tumor
overexpress
protein
breast
cancer
patient
may
use
conjunct
therapi
paclitaxel
taxol
antibodi
develop
human
murin
mab
insert
antigenbind
region
mab
framework
consensu
human
result
trastuzumab
cancer
cell
antigen
specif
tumor
tumorspecif
antigen
present
greater
concentr
normal
tumorassoci
antigen
antibodi
may
elimin
target
cell
complement
action
adcc
variabl
region
antibodi
recogn
attach
specif
antigen
constant
region
join
effector
cell
capabl
kill
target
cancer
cell
antigen
antibodi
bind
precipit
agglutin
may
isol
complex
antiidiotyp
mab
mimictumor
associ
antigen
also
may
use
cancer
therapi
idiotyp
network
hypothesi
formul
lindemann
jern
suggest
matur
b
cell
secret
antibodi
uniqu
antigenbind
specif
variabl
domain
refer
idiotyp
antiidiotyp
mab
gener
use
surrog
antigen
vaccin
immun
tumor
murin
antiidiotyp
mab
mimic
tumorassoci
antigen
recent
found
induc
specif
antiantiidiotyp
immun
respons
patient
platinumpretr
recurr
ovarian
cancer
enrol
phase
iii
clinic
trial
posit
immun
respons
associ
statist
signific
p
prolong
surviv
time
month
patient
shown
antiantiidiotyp
respons
compar
month
patient
antiantiidiotyp
neg
addit
peripher
blood
lymphocyt
mediat
lysi
express
tumor
cell
increas
patient
vaccin
mab
despit
use
murin
antibodi
studi
previou
phase
studi
involv
patient
ovarian
cancer
found
minim
side
effect
promis
earli
result
also
demonstr
patient
advanc
colorect
carcinoma
receiv
murin
antiidiotyp
mab
mimic
epitop
carcinoembryon
antigen
ceavac
patient
malign
melanoma
receiv
antiidiotyp
mab
trigem
mimic
disialogangliosid
despit
promis
develop
howev
still
sever
obstacl
effect
cancer
therapi
mab
problem
tumor
mab
conjug
characterist
continu
challeng
research
thu
far
chemotherapeut
mab
therapi
face
obstacl
due
poor
abil
agent
affect
tumor
cell
preferenti
healthi
cell
intrins
insensit
mani
tumor
drug
rapid
develop
resist
tumor
cell
mab
often
decreas
size
tumor
rare
lead
complet
remiss
solid
tumor
cellular
level
mab
low
dose
ideal
bind
excel
affin
antigen
identifi
express
exclus
tumor
cell
crossreact
mab
must
examin
histochem
test
tissu
section
anim
model
care
test
must
also
done
ensur
effector
molecul
drug
toxin
isotop
conjug
inadvert
target
healthi
cell
although
human
antibodi
greater
affin
murin
antibodi
potenti
yet
translat
improv
clinic
outcom
cancer
howev
recent
success
use
xenomous
technolog
develop
fulli
human
mab
specif
epiderm
growth
factor
receptor
indic
potenti
futur
advanc
area
recombin
immunotoxin
fusion
protein
contain
fv
mab
bacteri
toxin
develop
cancer
therapi
immunotoxin
exploit
variabl
regionbind
function
mab
theori
fragment
bind
region
bival
f
ab
fragment
monoval
fab
scfv
disulfidestabil
fv
fragment
may
use
oppos
larger
probabl
immunogen
whole
antibodi
disulfidestabil
fragment
may
stabl
higher
affin
antigen
scfv
linker
may
interfer
bind
fail
stabil
fragment
recombin
immunotoxin
deriv
pseudomona
enterotoxin
shown
activ
lymphoma
solid
tumor
leukemia
bind
specif
affin
key
element
known
form
immunoconjug
usual
effect
treat
human
tumor
anim
test
suggest
whole
antibodi
longer
halflif
bival
bind
effect
antibodi
fragment
decreas
bind
affin
bispecif
antibodi
singl
chain
fv
develop
may
effect
clear
faster
nontumor
tissu
deepli
penetr
tumor
whole
antibodi
bispecif
antibodi
may
use
target
tumor
vascular
endotheli
cell
therebi
limit
tumor
blood
suppli
possibl
inhibit
spread
advanc
radiolabel
allow
immunoconjug
deliv
cell
show
promis
clinic
trial
radioimmunotherapi
use
radiolabel
mab
deliv
radioact
isotop
target
cell
radioisotop
emitt
caus
damag
bound
cell
also
cell
adjac
tumor
cell
antibodi
may
abl
reach
within
tumor
lack
knowledg
appropri
dose
biodistribut
shed
antigen
hinder
use
radioisotop
radiolabel
mab
may
also
affect
normal
cell
depend
extent
reticuloendotheli
cell
express
fc
receptor
bind
constant
region
intact
antibodi
molecul
use
antibodi
fragment
construct
may
modifi
nonspecif
uptak
radiotherapi
exert
effect
emit
low
dose
exponenti
decreas
continu
radiat
antibodi
per
se
may
cytotox
effect
durat
radiotherapi
determin
halfliv
antibodi
isotop
use
success
radioimmunotherapi
affect
specif
affin
dose
immunoreact
antibodi
heterogen
antigen
express
diffus
rate
tumor
volum
blood
suppli
tumor
locat
dose
rate
effect
variabl
dose
deposit
choic
radionuclid
select
chelat
use
link
mab
radionuclid
mab
select
critic
develop
radiolabel
mab
suitabl
radio
nuclid
includ
first
radioisotop
use
treatment
hodgkin
diseas
lymphoma
potenti
use
lymphoma
therapi
decay
emiss
may
kill
tumor
cell
crossfir
effect
energi
releas
yttrium
time
higher
degrad
rapidli
uptak
tumor
cell
caus
toxic
addit
use
radiotherapi
radiolabel
mab
also
use
diagnos
cancer
radioact
isotop
link
mab
may
help
local
tumor
form
diagnost
imag
call
immunoscintigraphi
instanc
oncoscint
mab
coupl
may
use
detect
antigen
found
colorect
adenocarcinoma
mab
may
potenti
use
suppress
immun
system
transplant
induc
toler
transplant
organ
tissu
thu
far
howev
antibodi
licens
clinic
use
murin
antibodi
human
antibodi
receptor
use
reduc
allograft
reject
graftversushost
diseas
gvhd
complic
allogen
stem
cell
transplant
occur
despit
histocompat
test
use
cyclosporin
analog
gvhd
frequent
caus
ill
death
allogen
transplant
patient
occur
alloselect
donor
cell
recogn
interact
major
minor
histocompat
antiigen
host
lead
cytokin
releas
mab
therapi
gvhd
effect
administ
bone
marrow
transplant
gvhd
develop
target
tcell
activ
instanc
target
receptor
tac
protein
whose
express
crucial
step
activ
alloreact
cell
recent
report
daclizumab
human
antibodi
effect
complement
dual
immunosuppress
therapi
renal
transplant
patient
activ
cell
express
antibodi
cytokin
might
inhibit
cell
allograft
reject
prevent
gener
cytotox
cell
develop
hama
respons
patient
decreas
effect
murin
mab
rel
human
mab
thu
far
compromis
effect
approach
howev
human
antitac
mab
better
human
effector
function
may
surviv
longer
vivo
may
prove
less
immunogen
murin
counterpart
shortterm
antibodi
therapi
may
also
contribut
longterm
accept
skin
islet
allograft
even
gain
immunocompet
gener
abil
mab
induc
toler
transplant
tissu
selfantigen
may
hold
great
therapeut
potenti
mab
studi
although
thu
far
result
clinic
success
deplet
blockad
cell
antibodi
may
facilit
toler
prevent
cell
attack
graft
recent
cell
deplet
studi
primat
proven
promis
mab
treatment
complic
transplant
also
studi
includ
potenti
treatment
posttranspl
lymphoprolif
disord
mab
rituximab
use
mab
odulimomab
protect
ischemiareperfus
injuri
kidney
transplant
daclizumab
human
antibodi
target
anti
receptor
may
reduc
risk
acut
reject
renal
transplant
also
lower
cytomegaloviru
infect
rate
among
transplant
recipi
inflammatori
bowel
disord
known
crohn
diseas
also
treat
mab
therapi
chimer
antibodi
infliximab
remicad
act
bind
solubl
transmembran
tumor
necrosi
factor
prevent
bind
receptor
activ
macrophag
antibodi
may
provid
relief
patient
moder
sever
activ
crohn
diseas
addit
fda
recent
approv
infliximab
treatment
rheumatoid
arthriti
combin
methotrex
high
level
ige
may
caus
bronchial
hyperrespons
risk
factor
asthma
imtherapeut
applic
monoclon
antibodi
mune
respons
mediat
ige
import
pathogenesi
allerg
asthma
recent
studi
subject
report
moder
sever
allerg
asthma
twiceweekli
inject
recombin
human
antiig
antibodi
form
complex
free
ige
block
interact
mast
cell
basophil
led
fall
serum
ige
level
slightli
decreas
asthma
symptom
score
rel
placebo
group
patient
receiv
antiig
abl
reduc
relianc
corticosteroid
although
studi
must
interpret
cautious
nonetheless
promis
step
find
effect
asthma
therapi
approxim
case
sepsi
us
case
uk
report
year
mortal
rate
could
high
depend
popul
studi
mab
target
receptor
key
element
inflammatori
respons
unfortun
may
inhibit
mani
cytokin
impair
patient
abil
fight
infect
increas
risk
secondari
sepsi
also
inhibit
cytokin
may
suffici
although
mab
target
toward
compon
host
immun
system
individu
receptor
mediat
cell
help
treatment
septic
shock
target
bacteri
endotoxin
lipid
gramneg
bacteria
mab
may
efficaci
lipopolysaccharid
endotoxin
compon
outer
cell
membran
gramneg
bacteria
consist
highli
variabl
olink
polysaccharid
chain
r
core
region
lipid
turn
compos
glucosamin
disaccharid
backbon
substitut
amideand
esterlink
longchain
fatti
acid
believ
import
mani
case
septic
shock
septicemia
trigger
inflammatori
cascad
caus
seriou
injuri
even
death
lipid
link
core
region
olink
side
chain
variat
olink
side
chain
result
enorm
divers
among
gramneg
bacteria
make
adopt
immunotherapi
olink
antigen
determin
difficult
direct
antibodi
core
region
lipid
tend
conserv
would
allow
therapi
divers
array
gramneg
bacteria
favor
result
polyclon
antibodi
spur
attempt
develop
mab
murin
igm
mab
xoma
berkeley
ca
bind
epitop
lipid
e
coli
human
igm
centoxin
deriv
heterohybridoma
fuse
spleen
cell
patient
vaccin
e
coli
splenectomi
antibodi
thu
far
shown
mix
success
patient
sepsi
neither
current
clear
fda
therapeut
use
patient
bacteremia
often
endotoxemia
igm
antibodi
endotoxin
may
effect
endotoxin
bloodstream
well
unfortun
high
cost
antibodi
europ
combin
uncertainti
sepsi
caus
gramneg
bacteria
hinder
widespread
use
although
less
efficaci
option
may
target
recent
studi
report
high
rate
advers
reaction
patient
receiv
antibodi
antibodi
effect
placebo
given
control
subject
howev
research
mab
treatment
septicemia
continu
cytomegaloviru
cmv
caus
seriou
ill
affect
immunocompromis
patient
aid
undergo
organ
transplant
infect
rate
may
neg
cmv
receiv
kidney
seroposit
patient
cmv
infect
result
retin
gastroenter
hivinfect
patient
may
also
caus
chronic
intrauterin
infect
case
congenit
cmv
infect
report
year
mental
retard
hear
loss
may
occur
case
current
vaccin
cmv
ganciclovir
foscarnet
phosphonylmethoxi
propyl
cytosin
potenti
treatment
cmv
infect
anoth
mode
treatment
via
administr
anticmv
hyperimmunoglobulin
deriv
pool
sera
cmvseroposit
person
passiv
immun
shown
reduc
sever
cmv
prevent
mothertoinf
transmiss
moreov
antibodi
may
abl
clear
viru
infect
tissu
function
previous
thought
exclus
cytotox
lymphocyt
mani
physician
use
combin
antivir
agent
immunoglobulin
patient
risk
cmv
infect
mab
may
also
decreas
amount
antivir
agent
requir
treatment
mab
murin
cmv
polypeptid
shown
protect
anim
model
although
mab
may
act
synergist
foscarnet
ganciclovir
vitro
unclear
whether
advantag
could
extrapol
vivo
condit
experi
murin
cmv
use
model
system
suggest
high
concentr
antibodi
along
ganciclovir
phosphonylmethoxi
propyl
cytosin
synergist
inhibit
growth
murin
cmv
cell
cultur
wherea
lower
antibodi
concentr
produc
addit
effect
howev
antibodi
administ
along
ganciclovir
sever
combin
immunodefici
mice
also
produc
addit
effect
extent
mab
protect
host
cmv
infect
reliabl
predict
immunoreact
neutral
titer
vitro
antigenbind
data
mechan
action
mab
vitro
vivo
may
entir
differ
antibodi
use
along
drug
treatment
efficaci
improv
also
side
effect
high
drug
concentr
may
avoid
instanc
mg
ganciclovirkg
bodi
weight
along
antibodi
almost
effect
mgkg
ganciclovir
administ
alon
cmvinfect
sever
combin
immunodefici
mice
antibodi
human
direct
human
cmv
glycoprotein
margin
synergist
inhibit
cmv
vitro
conjug
ganciclovir
foscarnet
recent
trial
involv
aid
patient
activ
cmv
retin
rate
retin
progress
similar
group
receiv
antibodi
mg
intraven
week
placebo
control
group
surprisingli
mortal
increas
group
poor
perform
trial
may
due
inabl
antibodi
neutral
establish
cmv
infect
aid
patient
failur
cross
bloodocular
barrier
suffici
quantiti
liver
transplant
patient
also
risk
cmv
infect
may
requir
treatment
murin
mab
antit
cell
antibodi
direct
antigen
along
ganciclovir
mitig
transplant
reject
human
mab
neutral
cmv
test
safeti
pharmacokinet
period
day
bone
marrow
transplant
recipi
found
safe
efficaci
evidenc
steadi
increas
neutral
activ
also
human
anticmv
mab
design
purifi
hybridoma
gener
fusion
human
lymphocyt
mous
myeloma
cell
viru
neutral
titer
higher
produc
convent
human
globulin
use
human
human
mab
develop
bind
glycoprotein
gh
cmv
recogn
varieti
viru
strain
neutral
clinic
isol
cmv
could
use
potenti
agent
prevent
treatment
cmv
infect
human
respiratori
syncyti
viru
rsv
caus
seriou
lower
respiratori
tract
diseas
requir
consider
support
care
administr
humidifi
oxygen
respiratori
assist
fda
approv
use
human
mab
rsv
afflict
mostli
infant
children
younger
month
age
known
palivizumab
antibodi
produc
synagi
medimmun
inc
treatment
show
reduct
rsv
infect
hospit
patient
american
academi
pediatr
committe
infecti
diseas
publish
recommend
use
antibodi
children
risk
rsv
infect
mab
also
use
therapi
hsv
infect
incid
neonat
herp
babi
born
vagin
mother
primari
infect
babi
born
mother
recurr
infect
differ
attribut
passiv
transfer
protect
antibodi
fetu
antibodi
may
also
confer
partial
protect
type
strain
base
observ
potenti
mab
therapi
herp
studi
decad
experi
mice
instanc
indic
microgram
quantiti
antibodi
may
promot
heal
corneal
opac
blephar
caus
herp
simplex
howev
attempt
confer
immun
human
higher
anim
passiv
immun
alon
disappoint
antibodi
hsv
restrict
specif
epitop
among
glycoprotein
express
herp
viru
surfac
glycoprotein
gb
gd
gh
gk
gl
thought
crucial
infect
initi
step
hsv
infect
seem
bind
gc
heparan
sulfat
proteoglycan
follow
bind
gb
bind
gb
gc
stabil
gd
gh
involv
initi
viral
fusion
glycoprotein
may
help
expand
fusion
process
evid
neutral
antibodi
gh
gd
gb
prevent
membran
fusion
viral
attach
consist
model
human
antibodi
direct
gd
gb
epitop
mab
target
least
differ
antigen
site
hsv
glycoprotein
murin
model
glycoprotein
necessari
viru
replic
tissu
cultur
yamamoto
et
al
report
antibodydepend
cellular
cytotox
effect
neutral
mab
glycoprotein
b
hsv
athym
nude
mice
inocul
hsv
intracutan
administ
skin
lesion
heal
mice
given
antibodi
also
latent
infect
ganglia
prevent
mice
surviv
evidenc
failur
detect
hsv
upon
cocultiv
vero
cell
administr
develop
zosteriform
lesion
day
infect
reduc
viru
ganglia
prolong
surviv
time
howev
diseas
total
avoid
eventu
mice
succumb
diseas
antibodi
therapi
could
prevent
decreas
sever
herpet
kerat
iriti
blephar
corneal
infect
hsv
thu
mab
could
potenti
use
prevent
congenit
herp
sexual
transmiss
herp
viru
current
treatment
exist
hemorrhag
fever
caus
filoviru
ebola
recent
team
research
us
armi
medic
research
institut
identifi
protect
antibodi
direct
epitop
ebola
viru
membraneanchor
glycoprotein
antibodi
protect
mice
long
day
exposur
dose
equival
accept
mgkg
human
level
antibodi
specif
import
mab
studi
bound
ebola
zair
ivori
coast
sudan
serotyp
much
research
remain
done
potenti
antibodi
treatment
ebola
becom
realiz
toxin
poison
proteinac
substanc
antibodi
first
clinic
use
protect
toxin
digitali
today
antidigitali
immunotoxicotherapi
standard
therapi
digoxin
produc
sheep
immun
digoxinserum
albumin
conjug
igg
antibodi
specif
digoxin
purifi
cleav
fab
smaller
molecular
mass
fragment
allow
faster
renal
clearanc
rapid
action
whole
antibodi
fab
fragment
bind
circul
digitali
molecul
gener
complex
unabl
bind
receptor
advers
effect
rare
immunotherapi
gener
effect
digoxin
digitoxin
within
hour
howev
polyclon
antibodi
may
difficult
produc
may
caus
hypersensit
reaction
research
attempt
develop
human
mab
digoxin
toxin
exampl
group
use
transgen
mous
produc
hybridomasecret
human
mab
digoxin
recent
effect
goat
anticolchicin
igg
antibodi
studi
mice
expos
lethal
intraperiton
dose
antiinflammatori
colchicin
preliminari
studi
woman
colchicin
poison
show
promis
attempt
also
made
use
drugspecif
goat
antibodi
fragment
treat
antitricycl
antidepress
tca
overdos
antidepress
overdos
common
caus
intent
drug
overdos
us
howev
lethal
dose
tricycl
higher
colchicin
digoxin
snake
venom
requir
higher
antibodi
dose
sever
gkg
revers
toxic
highaffin
tricycl
antidepressantspecif
mab
shown
revers
cardiovascular
toxic
antidepress
desipramin
rat
prolong
surviv
tricycl
antidepressantspecif
fab
fragment
along
sodium
bicarbon
standard
treatment
tricycl
overdos
also
minim
requir
dose
antibodi
use
smaller
antibodi
fragment
singl
chain
fv
fragment
half
size
fab
may
also
promis
approach
singl
chain
fragment
retain
affin
shorter
halflif
bodi
monoclon
antibodi
may
also
help
allevi
poison
due
environment
contamin
hexachlorobiphenyl
paraquat
atrazin
chief
degrad
byproduct
insecticid
chloropyrifo
triclopyr
chloroprifosmethyl
chemic
may
soon
detect
remedi
help
antibodi
antibodi
may
also
use
treatment
poison
due
paraquat
hexachlorobiphenyl
domoic
acid
amnes
shellfish
poison
contamin
otherwis
difficult
remov
bodi
surround
environ
primari
target
mani
abus
drug
central
nervou
system
cn
immunotherapi
chemic
must
abl
penetr
cn
pcp
phencyclidin
angel
dust
type
arylcyclohexamin
affect
multipl
site
brain
link
violent
psychot
episod
similar
schizophrenia
treatment
difficult
known
antagonist
identifi
pcp
high
volum
distribut
clear
metabol
recent
mab
describ
could
bind
cocain
pcp
act
like
spong
bloodstream
prevent
reach
brain
shown
singl
dose
antibodi
reduc
pcp
effect
week
anim
might
equival
sever
month
human
highaffin
antibodi
fragment
pcp
function
better
fragment
bound
pcp
quickli
clear
bodi
whole
antibodybound
pcp
crystal
structur
antibodi
fragment
complex
pcp
studi
detail
antibodi
fragment
also
prefer
whole
antibodi
treatment
pcp
addict
lower
antigen
improv
pharmacokinet
antiidiotyp
antibodi
could
potenti
produc
drugmab
bind
site
mimic
drug
structur
featur
although
antibodi
cross
bloodbrain
barrier
increas
protein
bind
vascular
compart
lower
drug
volum
distribut
antibodi
act
like
pharmacokinet
antagonist
evid
antibodi
also
revers
effect
potent
arylcyclohexylamin
drug
suggest
antibodi
medic
use
treat
differ
class
drug
antipcp
igg
produc
hybridoma
cell
line
use
ascit
bioreactor
method
pharmacolog
immun
specif
antibodi
confirm
administ
antipcp
fragment
rat
three
differ
studi
without
produc
observ
effect
behavior
activ
immunotherapi
methamphetamin
addict
also
contempl
antibodi
therapi
cocain
addict
also
possibl
especi
develop
catalyt
antibodi
enzymelik
characterist
use
inactiv
drug
antibodi
esteras
activ
success
mimick
cocain
believ
metabol
vivo
esteras
antibodi
would
use
treatment
cocain
addict
catalyt
antibodi
probabl
would
use
highaffin
anticocain
antibodi
could
use
medic
emerg
part
withdraw
therapi
potenti
antibodi
applic
cocain
addict
test
rat
vaccin
approach
attach
cocain
molecul
carrier
protein
immun
rat
produc
antibodi
cocain
human
anticocain
antibodi
deriv
rat
produc
bacteria
catalyt
mab
recent
report
attenu
cocain
cardiovascular
effect
mice
conclus
year
elaps
sinc
edward
jenner
vaccin
young
child
smallpox
sinc
time
field
immunolog
evolv
rapid
pace
yield
mani
critic
develop
although
vaccin
thu
far
proven
costeffect
method
prevent
diseas
worldwid
develop
mab
use
specif
immunolog
respons
one
success
applic
immunolog
date
chimer
human
antibodi
reduc
risk
allergen
exposur
nonself
antibodi
heighten
clinic
effect
mab
treatment
develop
radiolog
pharmacolog
allow
radiolabel
immunoconjug
antibodi
produc
antibodi
fragment
heteropolym
bispecif
antibodi
avail
addit
whole
mab
promis
develop
may
soon
allow
mab
use
treat
afflict
vari
substanc
abus
cancer
asthma
viral
infect
septicemia
poison
heddi
zola
observ
therapeut
applic
mab
whilst
still
limit
scope
promis
break
substanti
shackl
realiz
potenti
forecast
propon
